Clinical Trial

Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance

Study acronym: MUS-AS
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Active surveillance is a common approach for men with low-risk or favorable intermediate-risk prostate cancer, aimed at avoiding or delaying treatment while closely monitoring the disease. Multiparametric MRI (mpMRI) is widely used to guide diagnosis and follow-up, but it can miss clinically significant prostate cancer and may be limited by access, cost, and variability in interpretation. Micro-ultrasound is a high-resolution ultrasound technique that may improve real-time detection of suspicious prostate lesions using a standardized scoring system (PRI-MUS). The purpose of this study is to evaluate the diagnostic performance of micro-ultrasound for detecting clinically significant prostate cancer in men with negative or stable mpMRI findings, either at initial diagnosis or during active surveillance follow-up. Participants will undergo micro-ultrasound assessment of the prostate. Areas considered suspicious on micro-ultrasound may be targeted for biopsy, followed by systematic prostate sampling. Biopsy results will be used as the reference standard to determine whether clinically significant prostate cancer is present. The study will assess measures such as sensitivity, specificity, and predictive values of micro-ultrasound, as well as procedure-related complications.
Trial Details
NCT Number NCT07386171
Lead Sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions Prostate Cancer, Active Surveillance for Prostate Cancer, Imaging Techniques
Enrollment 90 participants
Start Date 2026-03-01
Primary Completion 2027-03-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-04